Cancer patients who respond to experimental drugs get continued access in safety study

NCT ID NCT02632994

AVAILABLE Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study offers continued access to experimental oral cancer drugs for patients who are already benefiting from them in a previous Lilly study. The main goal is to monitor long-term safety. Participants must not be in any other conflicting research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY2503029, LY3023414, LY3838915, LY3847429 (oral cancer drugs)
What this could lead to: If successful, this study helps ensure patients who are benefiting from experimental cancer drugs can keep taking them while safety data is collected.
What could go wrong: This is an extension study, not a new treatment test. It does not prove the drugs work for new patients, and long-term side effects are still being monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Locations

Fort Wayne Oncology & Hematology
AVAILABLE

Fort Wayne, Indiana, 46804, United States
Sarah Cannon Cancer Center
AVAILABLE

Nashville, Tennessee, 37203, United States
UCLA Medical Center
AVAILABLE

Torrance, California, 90505, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.